The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis

July 1, 2021

Abstract

Peritoneal dialysis (PD) is a treatment modality for end-stage renal disease (ESRD) patients. Dextrose is a common osmotic agent used in PD solutions and its absorption may exacerbate diabetes mellitus, a common complication of ESRD. PD solutions also contain glucose degradation products (GDPs) that may lead to encapsulating peritoneal sclerosis (EPS), a severe complication of PD. A previous study showed that far-infrared (FIR) therapy improved a patient’s gastrointestinal symptoms due to EPS. Due to limited literature on the matter, this study aims to investigate dialysate GDPs and peritoneal function in diabetic patients on PD. Thirty-one PD patients were enrolled and underwent 40 min of FIR therapy twice daily for six months. We demonstrated the effect of FIR therapy on the following: (1) decrease of methylglyoxal (p = 0.02), furfural (p = 0.005), and 5-hydroxymethylfurfural (p = 0.03), (2) increase of D/D0 glucose ratio (p = 0.03), and (3) decrease of potassium levels (p = 0.008) in both DM and non-DM patients, as well as (4) maintenance and increase of peritoneal Kt/V in DM and non-DM patients, respectively (p = 0.03). FIR therapy is a non-invasive intervention that can decrease dialysate GDPs in PD patients by improving peritoneal transport rate and solute removal clearance, while also maintaining dialysis adequacy.

-Int J Mol Sci. 2021 Apr 2;22(7):3732.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY

FIRAPY to Exhibit at 70th JSDT Annual Meeting in Yokohama

June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
FIRAPY was showcased at ERA 2025 in Vienna, where we reconnected with partners and met new potential

FIRAPY Showcased at ERA 2025 in Vienna

June 8, 2025
FIRAPY Medical was honored to exhibit at ERA 2025 , held at Austria Center Vienna from June 4–7, 2025 . This event marked FIRAPY’s first return to the ERA Congress since the global COVID-19 pandemic , and an important milestone in reconnecting with the European nephrology community. During the congress, our booth (X1.200) attracted considerable attention from both existing partners and new contacts. We were very encouraged by the many productive conversations and the strong interest shown by nephrology professionals across different regions. It was a great pleasure to meet some of our long-standing friends at the event, including: Stanningley Pharma (UK) — our valued distribution partner in the UK for more than 15 years Dr. Dan Heristea (France) — a nephrology expert and friend of FIRAPY Nordic MedCom (Nordic) — a familiar face from past interactions in the industry We were equally pleased to engage with potential new partners from Canada, Morocco, Panama, and the UAE . We look forward to the possibility of building new collaborations to further extend the clinical benefits of FIRAPY to more patients worldwide.  We sincerely thank everyone who visited our booth and supported us throughout the congress. We look forward to continuing these conversations and working together to advance vascular access care and patient outcomes through FIRAPY.

FIRAPY Expands Local Engagement in Thailand Through Two Key Vascular Access Events

May 26, 2025
FIRAPY was presented at two key vascular access events in Thailand, engaging with surgeons, nephrologists, and dialysis nurses on its growing clinical applications.
More Posts